Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1841 • ACR Convergence 2023
Clinical Trial Perceptions Among Male Patients with Systemic Lupus Erythematosus (SLE): Georgians Organized Against Lupus (GOAL) Cohort
Hilton Mozee¹, Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Kim Schofield², Jessica Williams³ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²Georgia State Rep. HD 63, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Minority patients are disproportionately affected by SLE. Yet, they are underrepresented in SLE clinical trials compared to White patients. Specifically, patients that identify as…
Abstract Number: 2258 • ACR Convergence 2023
Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task
Michelle Barraclough¹, Shane McKie², Alex Kafkas², Ben Parker³, Juan Pablo Diaz Martinez⁴, Andrea Knight⁵, Kathleen Bingham¹, Jiandong Su¹, Mahta Kakvan⁶, Carolina Munoz-Grajales⁷, Carmela Tartaglia⁸, Lesley Ruttan⁹, Joan Wither¹, Dennisse Bonilla¹, Daniela Montaldi², Rebecca Elliott², Patti Katz¹⁰, Dorcas Beaton¹¹, Robin Green⁹, Ian Bruce² and Zahi Touma¹², ¹University Health Network, Toronto, ON, Canada, ²University of Manchester, Manchester, United Kingdom, ³Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁴Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷UHN/TWH, Toronto, ON, Canada, ⁸Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁹University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ¹⁰University of California San Francisco, San Rafael, CA, ¹¹Institute for Work & Health, Toronto, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a significant problem in SLE but there is a disconnect between objective and subjective CI. This makes it difficult to…
Abstract Number: 2274 • ACR Convergence 2023
Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse
Chak Kwan Cheung¹, Chak Sing Lau² and Shirley Chiu Wai Chan³, ¹Divison of Rheumatology and Clinical Immunology, Queen Mary Hospital, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, ²University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Lupus nephritis (LN) is a significant comorbidity affecting approximately up to 50-60% of patients with systemic lupus erythematosus (SLE). Complete renal response (CRR) and…
Abstract Number: 2292 • ACR Convergence 2023
Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?
Dina Zucchi¹, Giancarlo Cascarano², Antonio Collesei³, Elena Elefante², Francesca Monacci⁴, Chiara Ietto⁴, Linda Carli², Sabrina Gori², Valentina Gelsi⁴, Chiara Tani² and Marta Mosca², ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Familial Cancer Clinics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy, ⁴Department of Clinical and Experimental Medicine, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients are at risk of disease flare during pregnancy; risk stratification is crucial for personalized treatment and monitoring. Our hypothesis…
Abstract Number: 2308 • ACR Convergence 2023
The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort
Amanda King¹, Catherine Brown², Cleopatra Altenor¹, Timothy Niewold³ and Ashira Blazer³, ¹Bay Medical Centre, Castries, Saint Lucia, ²The University of the West Indies, Bridgetown, Barbados, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Poverty increases non-communicable disease risk, however its influence on systemic lupus erythematosus (SLE) burden is poorly understood. Non-White racial/ethnic groups, particularly of African origin,…
Abstract Number: 2324 • ACR Convergence 2023
Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Lixia Yao, Liwam Gebru, Biruk Aweke, Jay Patel, Ernest Vina, David Fleece and Huanmei Wu, Temple University, Philadelphia, PA
Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…
Abstract Number: 2343 • ACR Convergence 2023
Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications
Eduardo Mantovani Cardoso¹, Rachel Simon¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by multi-systemic involvement and difficult-to-predict disease flares. Hydroxychloroquine (HCQ) has long been recognized as…
Abstract Number: 2456 • ACR Convergence 2023
Lupus Patient Navigator Program to Improve Healthcare Barriers for Minority Patients
Samiha Karim¹, Gary Link¹, Dulaney Wilson¹, Jim Oates¹, Gary Gilkeson¹, Jasvinder Singh² and Diane L. Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Despite recent progress in diagnosis and treatment of SLE minorities continue to bear the greater burden of disease with disproportionately higher morbidity and mortality.…
Abstract Number: 2535 • ACR Convergence 2023
Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management
Katherine Carpenter¹, Melissa French², Sarah Gilman³, Sara Johnson⁴, Patricia Castle⁴, S. Sam Lim⁵, Charmayne Dunlop-Thomas⁵, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Alexandria, VA, ³Wayfinder Health Strategies, Falls Church, VA, ⁴Pro-Change Behavior Systems, Inc., Narragansett, RI, ⁵Emory University, Atlanta, GA
Background/Purpose: The Lupus Foundation of America (LFA) has engaged in a 5-year cooperative agreement with the Centers for Disease Control and Prevention to implement a…
Abstract Number: PP17 • ACR Convergence 2023
Utilizing Support Networks to Improve Patient Outcomes
Brian Vogel, Lupus and Allied Diseases Association, Inc., San Diego, CA
Background/Purpose: In 2006, I realized I was gay and identified as LGBTQIA but did not come out. In 2008, I began experiencing chronic widespread pain,…
Abstract Number: 0080 • ACR Convergence 2023
Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
Neha Bhagwat¹, Kumar Penmetsa², Matt Devalaraja³, Suzana Marusic⁴, Cornelia M. Weyand⁵, Shozo Ohtsuki⁶, Peggy Scherle¹ and Kris Vaddi¹, ¹Prelude Therapeutics, Inc, Wilmington, DE, ²Thermo Fisher Scientific, Philadelphia, PA, ³Nipuna Therapeutics, Waltham, MA, ⁴Hooke Laboratories LLC, Lawrence, MA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁶Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN
Background/Purpose: Protein arginine methyltransferase 5 (PRMT5) is the major type II PRMT that catalyzes the formation of symmetrical dimethyl arginine (SDMA) on protein substrates and…
Abstract Number: 0181 • ACR Convergence 2023
Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States
Emily Cosentino, John Pearce and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is more prevalent and has greater adverse health outcomes in women, minorities, and individuals with low socioeconomic status (SES), particularly…
Abstract Number: 0334 • ACR Convergence 2023
Association of a Self-Report Screening Tool for Sarcopenia (SARC-F) with Functional Status Outcomes in Systemic Lupus Erythematosus
Sarah Lieber¹, Yvonne Shea², Deanna Jannat-Khah², John Carrino², M. Carrington Reid³ and Lisa Mandl¹, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Weill Cornell Medicine, New York, NY
Background/Purpose: Sarcopenia, i.e., loss of skeletal muscle mass and strength, has been associated with multiple adverse health outcomes, including mortality. Although limited data suggest that…
Abstract Number: 0552 • ACR Convergence 2023
The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus
YuFang Ding¹, Can Huang², Jiuliang zhao³, Qian Wang¹, Xinping Tian³, Mengtao Li³ and xiaofeng Zeng¹, ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Unoin Medical College Hospital, Beijing, China, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases (23·3 events per 1000 patient-years). Antiphospholipid antibodies (aPLs), including anticardiolipin…
Abstract Number: 0569 • ACR Convergence 2023
Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus
Risa Wakiya¹, Hiromi Shimada¹, Shusaku Nakashima¹, Taichi Miyagi², Yusuke Ushio³, Koichi Sugihara⁴, Mao Mizusaki¹, Rina Mino⁵, Kanako Chujo⁶, Ryoko Kagawa³, Hayamasa Yamaguchi³, Tomohiro Kameda¹ and Hiroaki Dobashi¹, ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁴Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: S100, a damage-related molecular pattern factor, was reported to be a biomarker associated with disease activity in SLE. Additional hydroxychloroquine, which could regulate IFN…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].